litlas
Log inCreate account

Werner Scheithauer

Active 1985–2022

80
Papers
29,170
Citations
67
h-index
80
i10-index

Citations

Citations per year for Werner Scheithauer1952: 1 citations1985: 2 citations1986: 8 citations1987: 4 citations1988: 4 citations1989: 6 citations1990: 2 citations1991: 8 citations1992: 2 citations1993: 3 citations1994: 4 citations1995: 16 citations1996: 17 citations1997: 17 citations1998: 15 citations1999: 25 citations2000: 19 citations2001: 27 citations2002: 36 citations2003: 24 citations2004: 58 citations2005: 81 citations2006: 54 citations2007: 87 citations2008: 135 citations2009: 202 citations2010: 267 citations2011: 201 citations2012: 233 citations2013: 184 citations2014: 221 citations2015: 226 citations2016: 209 citations2017: 270 citations2018: 225 citations2019: 860 citations2020: 861 citations2021: 814 citations2022: 490 citations2023: 347 citations2024: 544 citations2025: 196 citations2026: 7 citations1953–1984: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,709 citing papers, 19% of this breakdownChina: 803 citing papers, 9% of this breakdownItaly: 726 citing papers, 8.1% of this breakdownUnited Kingdom: 578 citing papers, 6.4% of this breakdownGermany: 572 citing papers, 6.4% of this breakdownFrance: 540 citing papers, 6% of this breakdownJapan: 431 citing papers, 4.8% of this breakdownSpain: 360 citing papers, 4% of this breakdownNetherlands: 352 citing papers, 3.9% of this breakdownBelgium: 246 citing papers, 2.7% of this breakdownCanada: 232 citing papers, 2.6% of this breakdownAustralia: 217 citing papers, 2.4% of this breakdown
0%19%Other 24.7%

Institutions

Fields

  • Medicine79.8%
  • Biochemistry, Genetics and Molecular Biology13%
  • Immunology and Microbiology2.4%
  • Computer Science1.4%
  • Neuroscience0.7%
  • Materials Science0.7%
  • Other2%

Topics

  • Colorectal Cancer Treatments and Studies12.9%
  • Hepatocellular Carcinoma Treatment and Prognosis5.7%
  • Pancreatic and Hepatic Oncology Research5.3%
  • Colorectal Cancer Surgical Treatments5.2%
  • Cancer Genomics and Diagnostics3.6%
  • Genetic factors in colorectal cancer3.6%
  • Other63.7%

Coauthors

All papers

Open in search
  1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    Authors: Eric Van Cutsem, Andrés Cervantes, René Adam, Alberto Sobrero, J. Han van Krieken, Dan Aderka, E. Aranda Aguilar, Alberto Bardelli, Al B. Benson, G. Bodoky, Fortunato Ciardiello, André D’Hoore, Eduardo Díaz‐Rubio, Jean‐Yves Douillard, Michel Ducreux, Alfredo Falcone, Axel Grothey, Thomas Gruenberger, Karin Haustermans, Volker Heinemann, Paulo M. Hoff, C.-H. Köhne, Roberto Labianca, Pierre Laurent‐Puig, Brigette Ma, Tim Maughan, Kei Muro, Nicola Normanno, Pia Österlund, Wim J.G. Oyen, Demetris Papamichael, George Pentheroudakis, Per Pfeiffer, Timothy Price, Cornelis J.A. Punt, Jens Ricke, A. Roth, Ramón Salazar, Werner Scheithauer, Hans‐Joachim Schmoll, Josep Tabernero, Julien Taı̈eb, Sabine Tejpar, Harpreet Wasan, Takayuki Yoshino, Aziz Zaanan, Dirk Arnold - Annals of Oncology 2016 cited by 3,449

  2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

    Authors: Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, N. Niederle, A. Rost, Heinz‐Gert Höffkes, Markus Moehler, Reinhard Udo Lindig, Dominik Paul Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing - The Lancet Oncology 2014 cited by 1,741

  3. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

    Authors: Bernard Nordlinger, Halfdan Sørbye, Bengt Glimelius, Graeme J. Poston, Peter M. Schlag, Philippe Rougier, Wolf O. Bechstein, John N Primrose, Euan Walpole, Meg Finch-Jones, Daniel Jaeck, Darius Mirza, Rowan W. Parks, Murielle Mauer, E. Tanis, Eric Van Cutsem, Werner Scheithauer, Thomas Gruenberger - The Lancet Oncology 2013 cited by 1,316

  4. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

    Authors: Thierry André, Armand de Gramont, Déwi Vernerey, Benoist Chibaudel, Franck Bonnetain, Annemilaï Tijeras‐Raballand, Aurélie Scriva, Tamas Hickish, Josep Tabernero, Jean‐Luc Van Laethem, Maria Banzi, E. Maartense, Einat Shmueli, Göran Carlsson, Werner Scheithauer, Demetris Papamichael, M. Moehler, Stefania Landolfi, Pieter Demetter, Soudhir Colote, Christophe Tournigand, Christophe Louvet, Alex Duval, Jean-François Fléjou, Aimery de Gramont - Journal of Clinical Oncology 2015 cited by 675

  5. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

    Authors: Leonard B. Saltz, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai‐Shen Yang, Fernando Rivera, Félix Couture, Florin Sirzén, Jim Cassidy - Journal of Clinical Oncology 2008 cited by 2,963

  6. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    Authors: Hans‐Joachim Schmoll, Eric Van Cutsem, Alexander Stein, Vincenzo Valentini, Bengt Glimelius, Karin Haustermans, Bernard Nordlinger, Cornelis JH van de Velde, Judith Balmañà, Jarosław Reguła, Irıs D. Nagtegaal, Geerard L. Beets, Dirk Arnold, Fortunato Ciardiello, Paulo M. Hoff, David J. Kerr, C.-H. Köhne, Roberto Labianca, Timothy Price, Werner Scheithauer, Alberto Sobrero, Josep Tabernero, Dan Aderka, Sérgio Barroso, G. Bodoky, Jean‐Yves Douillard, Hesham El Ghazaly, J. Gallardo, A. Garin, Rob Glynne‐Jones, Karin Jordan, Andrey Meshcheryakov, Demetris Papamichail, Per Pfeiffer, Ioannis Souglakos, Serdar Turhal, Andrés Cervantes - Annals of Oncology 2012 cited by 1,534

  7. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

    Authors: Bernard Nordlinger, Halfdan Sørbye, Bengt Glimelius, Graeme J. Poston, Peter M. Schlag, Philippe Rougier, Wolf O. Bechstein, John N Primrose, Euan Walpole, Meg Finch-Jones, Daniel Jaeck, Darius Mirza, Rowan W. Parks, Laurence Collette, Michel Praet, Ullrich Bethe, Eric Van Cutsem, Werner Scheithauer, Thomas Gruenberger - The Lancet 2008 cited by 1,945

  8. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

    Authors: Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah-Edin Al-Batran, Tobias Heintges, Christoph Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Markus Moehler, Werner Scheithauer, Swantje Held, Lisa Miller‐Phillips, Dominik Paul Modest, Andreas Jung, Thomas Kirchner, Sebastian Stintzing - British Journal of Cancer 2020 cited by 188

  9. nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

    Authors: David Goldstein, Robert H. El-Maraghi, Pascal Hammel, Volker Heinemann, Volker Kunzmann, Javier Sastre, Werner Scheithauer, Salvatore Siena, Josep Tabernero, Luís Teixeira, Giampaolo Tortora, Jean‐Luc Van Laethem, Rosemary Young, Darryl Penenberg, Brian Lu, Alfredo Romano, Daniel D. Von Hoff - JNCI Journal of the National Cancer Institute 2015 cited by 663

  10. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

    Authors: Sebastian Stintzing, Dominik Paul Modest, Lisa Rossius, Markus M. Lerch, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Swantje Held, Clemens Gießen-Jung, Markus Moehler, A. Jagenburg, Thomas Kirchner, Andreas Jung, Volker Heinemann - The Lancet Oncology 2016 cited by 418

  11. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality

    Authors: Noémi Pávó, Markus Raderer, Martin Hülsmann, Stephanie Neuhold, Christopher Adlbrecht, Guido Strunk, Georg Goliasch, Heinz Gisslinger, Günther Steger, Michael Hejna, Wolfgang J. Köstler, Sabine Zöchbauer‐Müller, Christine Marosi, Gabriela Kornek, Leo Auerbach, Sven Schneider, Bernhard Parschalk, Werner Scheithauer, Robert Pirker, Johannes Drach, Christoph Zielinski, Richard Pacher - Heart 2015 cited by 270

  12. Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

    Authors: David Cunningham, Ian Chau, Deborah Stocken, Juan W. Valle, David B. Smith, William P. Steward, Peter Harper, Janet Dunn, Catrin Tudur Smith, Julia West, Stephen Falk, A. Crellin, F. Adab, Joyce Thompson, Pauline Leonard, J. Ostrowski, Martin Eatock, Werner Scheithauer, Richard Herrmann, John P. Neoptolemos - Journal of Clinical Oncology 2009 cited by 818

  13. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

    Authors: Sebastian Stintzing, Pratyaksha Wirapati, Heinz‐Josef Lenz, Daniel Neureiter, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Markus Moehler, Werner Scheithauer, Swantje Held, Dominik Paul Modest, Andreas Jung, Thomas Kirchner, Dan Aderka, Sabine Tejpar, Volker Heinemann - Annals of Oncology 2019 cited by 194

  14. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

    Authors: Eric Van Cutsem, Walter L. Vervenne, Jaafar Bennouna, Yves Humblet, Sharlene Gill, Jean‐Luc Van Laethem, Chris Verslype, Werner Scheithauer, Aijing Shang, Jan Cosaert, Malcolm J. Moore - Journal of Clinical Oncology 2009 cited by 643

  15. Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

    Authors: Jim Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai‐Shen Yang, Fernando Rivera, Félix Couture, Florin Sirzén, Leonard B. Saltz - Journal of Clinical Oncology 2008 cited by 864

  16. EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

    Authors: Alberto Sobrero, Joan Maurel, Louis Fehrenbacher, Werner Scheithauer, Yousif Abubakr, Manfred P. Lutz, M. E. Vega-Villegas, Cathy Eng, E.U. Steinhauer, Jana Prausová, Heinz‐Josef Lenz, Christophe Borg, Gary Middleton, H. Kröning, Gabriele Luppi, O. Kisker, Angela Zubel, Christiane Langer, Justin Kopit, Howard A. Burris - Journal of Clinical Oncology 2008 cited by 952

  17. Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients

    Authors: J. Thaler, Cihan Ay, Nigel Mackman, Rogier M. Bertina, Alexandra Kaider, Christine Marosi, Nigel S. Key, D. Anthony Barcel, Werner Scheithauer, Gabriela Kornek, Christoph Zielinski, Ingrid Pabinger - Journal of Thrombosis and Haemostasis 2012 cited by 269

  18. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

    Authors: Sebastian Stintzing, Lisa Miller‐Phillips, Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, S-E. Al-Batran, Tobias Heintges, Christoph Kahl, G. Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Swantje Held, Markus Moehler, A. Jagenburg, Thomas Kirchner, Andreas Jung, Volker Heinemann - European Journal of Cancer 2017 cited by 139

  19. Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

    Authors: Chris Twelves, A. Wong, Marek P. Nowacki, Markus Abt, Howard A. Burris, Alfredo Carrato, Jim Cassidy, Andrés Cervantes, Jan Fagerberg, Vassilis Georgoulias, Fares Husseini, Duncan I. Jodrell, P. Koralewski, H. Kröning, Jean A. Maroun, Norbert Marschner, Joseph McKendrick, Marek Pawlicki, Riccardo Rosso, Johannes Schüller, Jean‐François Seitz, Borut Štabuc, Jerzy Tujakowski, Guy van Hazel, J. Załuski, Werner Scheithauer - New England Journal of Medicine 2005 cited by 1,247

  20. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

    Authors: Werner Scheithauer, Harald Rosén, Gabriela Kornek, Christian Sebesta, D. Depisch - BMJ 1993 cited by 659

  21. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

    Authors: J Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Karen Rittweger, Frank Gilberg, Leonard B. Saltz - British Journal of Cancer 2011 cited by 227

  22. Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

    Authors: Richard Herrmann, G. Bodoky, Thomas Ruhstaller, Bengt Glimelius, Emilio Bajetta, Johannes Schüller, Piercarlo Saletti, Jean Bauer, Arié Figer, Bernhard C. Pestalozzi, Claus‐Henning Köhne, Walter Mingrone, Salomon M. Stemmer, Karin Rita Tamas, Gabriela Kornek, Dieter Koeberle, Susanne Cina, Jürg Bernhard, Daniel Dietrich, Werner Scheithauer - Journal of Clinical Oncology 2007 cited by 591

  23. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

    Authors: Viviane Hess, Bengt Glimelius, Philipp Grawe, Daniel Dietrich, G. Bodoky, Thomas Ruhstaller, Emilio Bajetta, Piercarlo Saletti, Arié Figer, Werner Scheithauer, Richard Herrmann - The Lancet Oncology 2008 cited by 238

  24. Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial

    Authors: Arndt Stahler, Sebastian Stintzing, Jobst C. von Einem, C. Benedikt Westphalen, Kathrin Heinrich, Nicole Krämer, Marlies Michl, Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Markus Moehler, Florian Kaiser, Thomas Kirchner, Andreas Jung, Volker Heinemann - European Journal of Cancer 2020 cited by 25